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In the last century, the average health of  the American people has im- 
proved dramatically. The mean life expectancy of Americans has increased 
almost twenty years, or two years per decade,’ since the turn of the cen- 
tury. Just from 1979 to 1988, the age-adjusted mortality rate declined 7.2 
percent. 
An important part of this enormous progress in health (which is scarcely 
reflected in our national accounts) is probably due to large private and pub- 
lic investments in biomedical research. In  1993, health R&D accounted 
for 18 percent of total U.S.  R&D expenditure. Health R&D expenditures, 
by  source of funding, are shown in table 15.1. 
The National Institutes of Health (NIH) administer about 80 percent 
of federal health R&D.  The NIH is made up of twenty-one institutes and 
centers, each with a mission and a separate, annual budget established by 
Congress. The institutes and centers are listed in table  15.2, along with 
the year in which each was established and its fiscal year  1998 budget 
obligations.2  NIH does not want people to be misled by the names of  the 
institutes; it points out that “research on any disease is not confined to 
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565 Table 15.1  Health R&D Expenditures 
1993 Health 
Source of Funding  R&D Funds 
Federal  12,051 
State and local  2,054 
Industry  15,711 
Private nonprofit  1,215 
All sources  31,032 
Source: National Center for Health Statistics 1995, table 132. 
Note; Figures are in millions of dollars. 
Table 15.2  NIH Institute and Centers 
Year  1998 Obligations 
Established  (million $) 
National Cancer Institute 
National Institute of Mental Health 
National Heart, Lung, and Blood Institute 
National Institute of Allergy and Infectious 
National Institute of Dental Research 
National Institute of Diabetes and Digestive 
National Institute of Neurological Disorders 
National Center for Research Resources 
National Institute of Child Health and Human 
National Institute of General Medical Sciences 
National Institute of Environmental Health 
National Eye Institute 
National Library of Medicine 
John E. Fogarty International Center 
National Institute on Alcohol Abuse and 
National Institute on Aging 
National Institute on Drug Abuse 
National Institute of Arthritis and 
Musculoskeletal and Skin Diseases 
National Institute of Nursing Research 
National Institute on Deafness and Other 
National Human Genome Research Institute 
Diseases 
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one Institute, and no Institute is dedicated to a single disease. An Insti- 
tute’s budget is an inadequate measure of support for research on specific 
diseases. Research into many diseases is often carried on in several Insti- 
tutes simultaneously, e.g.,  several Institutes are supporting research on 
Alzheimer’s disease.” 
While the NIH focuses much of its research on combating specific dis- 
eases, and much of its funding supports research projects that are of obvi- 
ous relevance to specific diseases, the NIH also places a high priority on 
funding basic research. These basic research projects may appear initially 
to be unrelated to any specific disease, but might prove to be a critical 
turning point in a long chain of discoveries leading to improved health. 
Each of the NIH institutes supports basic research likely to advance par- 
ticular areas of science that might prove relevant to clinical problems im- 
portant to that institute’s mission. By supporting disease-related  and basic 
research projects simultaneously, the NIH seeks to achieve both near-term 
improvements in the diagnosis, treatment, and prevention of specific dis- 
eases and long-term discoveries in basic science that in time will produce 
great advances in our ability to understand, treat, and prevent disease or 
delay its onset. 
In this paper I develop a simple theoretical model of the allocation of 
the applied component of  public biomedical research expenditure-the 
approximately 50 percent of expenditure that is of direct, near-term rele- 
vance to specific diseases-and  present some empirical evidence about the 
determinants of this allocation. The implications of the theoretical model 
are consistent with government officials’ descriptions of the allocation pro- 
cess: The structure of expenditure should depend upon research produc- 
tivity (or “scientific opportunity”) as well as on public health need, that 
is, the societal and economic burden of  the disease/condition. Although 
we lack, at this point, useful indicators of research productivity (i.e., of the 
cost of  achieving research advances), we  have a number of  measures of 
disease burden (i.e., of the benefit of achieving these  advance^).^ Analysts 
of technical change typically have data on neither the costs nor the benefits 
of  technical advance. Failure to measure research productivity will  not 
necessarily bias my  estimates; if it does, it seems likely to bias them to- 
ward zero. 
The paper  is organized as follows. In the next  section I develop the 
simple model of  public research expenditure allocation. I rely on three 
types and sources of data to estimate the parameters of the model: data 
on research activity derived from NIH’s CRISP (Computerized Retrieval 
of Information on Scientific Projects) database, premature mortality data 
3. The disease burden is the potential benefit (ignoring all comorbidities), not the actual 
benefit. 568  Frank  R. Lichtenberg 
from the Vital Statistics-Mortality  Detail file, and data on chronic condi- 
tion prevalence and severity from the National Health Interview Survey. 
These are discussed in section 15.2. Preliminary estimates are presented in 
section 15.3, and a summary is provided in section 15.4. 
15.1  A Simple Model of the Determinants of 
Research Expenditure at the Disease Level 
To motivate the discussion and develop a few intuitions, I write down 
the simplest possible model of research funding allocation. This model is 
based on the following extremely strong assumptions (some of which are 
relaxed below): (1) there are only two diseases; (2) the number of people 
suffering from the two diseases, N,  and N2,  is exogenous; (3) the average 
severity of the two diseases is identical; (4) the probability P,  of finding a 
cure for disease i(i  = 1, 2) is a concave (deterministic) function of research 
funding for that disease, X,: P,  = X;, where 0 <  01  < 1;4 (5) the effect of 
funding on the probability of finding a cure is the same across diseases; 
and (6)  the total research budget X = XI + X2  is fixed. 
Suppose that  policymakers attempt to maximize the (expected) total 
number of people cured of both diseases subject to the budget con~traint,~ 
that is, they choose Xi to maximize 
(1)  J* = NIP,  + N,P, 
=  N,Xp + N,X,” 
= NIX?  + N,(X - Xi).. 
The first-order condition implies that relative funding of research on the 
two diseases should satisfy 
(2)  ln(X,/X,) = [l/(l - a)]ln(Nl/N2). 
Research funding should increase with disease incidence: for example, XI 
> X, if  N, > N2. This is because the benefit of discovering a cure for 
the disease is proportional to its incidence, but the cost is independent of 
incidence. Moreover the elasticity  of funding with respect  to incidence 
should exceed unity: if disease 1 is twice as prevalent as disease 2, research 
funding for disease 1 should be more than twice as great as research fund- 
4. Viscusi (1995, 3) notes that “in the case of  biomedical research, the typical outcome 
will be a change in societal risk levels induced by the biomedical research outcomes.” 
5. I assume for simplicity that federal policymakers do not pay attention to biomedical 
R&D funded by  other sources; in other words, they are not merely trying to “fill gaps” in 
other research, nor do they consider the potential impact of public R&D on other research 
activity. Took (2000), however, presents evidence that suggests that public biomedical re- 
search may have a significant, albeit very delayed, impact on private drug discovery. The Allocation of Publicly Funded Biomedical Research  569 
ing for disease 2.6 Equalizing research expenditure per victim across dis- 
eases would be inefficient. 
One could generalize this model to the case of I > 2 diseases, to obtain 
I -  1 equilibrium conditions of the form 
(3)  lnX, = constant  + [l/(l - a)]lnNt, 
(i = 1, 2, . . . , I - 1). Given cross-sectional or panel data on research 
funding and incidence by  disease, one could estimate equation (3) to test 
the hypothesis of  diminishing returns to research funding at the disease 
level  and to estimate the parameter  a.  But  this simple model can and 
should be extended in at least two directions: We should allow for multiple 
indicators of incidence and for differences in research productivity (scien- 
tific opportunity) across diseases. 
15.1.1  Multiple Indicators of Incidence 
As the director of NIH says, a given disease imposes a number of differ- 
ent kinds of  burden on society, and “policy makers will need to consider 
the relative importance or weight to be placed on each criteri[on] when 
assessing the overall societal burden imposed by each disease.” While the 
NIH has indicated interest in determining how to measure public health 
burden, it has also expressed uncertainty about how to do so. I now outline 
a procedure for doing this.’ Then I will perform empirical analysis to as- 
certain how close the actual allocation of research resources is to the allo- 
cation that is optimal, according to my framework. The answer appears to 
be “pretty close.” 
Suppose that the overall burden of a disease is perceived by policymak- 
ers to be a function of K attributes of the disease: N, =  AAl,,  A2,, . . . , 
AK,) where, for example, A1 is the number of deaths, A2 is the number of 
bed-disability days, A3 is the number of hospital stays, and so forth. Fur- 
ther suppose that the functional form of this relationship is 
(4)  lnN, = p,lnAl, + p,lr1A2~  + ... + p,lnAK,, 
where C,p,  = 1. The term p,  reveals the relative “weight” assigned by 
policymakers to attribute k  in the determination of overall disease burden. 
Substituting equation (4) into equation (3), 
6.  In reality, finding a cure for one of the diseases may increase the probability of suffering 
at a future date from the other disease. Development of a richer model to account for this 
and other complications is a challenging task. Given the stark simplicity of my model, it may 
be best to view it as a set of organizing principles that can be used to interpret the allocative 
process, rather than as a theory. 
7. Recently a National Academy of Sciences panel looked at priority setting at NIH, and 
recommended using a number of measures to measure burden of illness in a fashion similar 
to what I propose. See Institute of Medicine (1998). 570  Frank R. Lichtenberg 
(5)  lnX8  = constant + [l/(l -  a)] 
(PllnA1, + p2lnA2(  + ... + pKlnAKI), 
Estimation  of equation (5) would provide estimates of these (“revealed 
preference”) weights as well  as of the technological parameter  a. They 
would indicate the relative weight given to mortality  and bed-disability 
days, for example. 
Since disease outcome and incidence data are available by demographic 
group, we can also make inferences about weights associated with different 
demographic groups.8 For example, let us define “adjusted” bed-disability 
days A2*  = A2YOUNG + (1 + 0)  A20LD, where A2YOUNG  and 
A20LD denote bed-disability days of young and old people, respectively. 
If policymakers’ evaluation of the marginal burden of the two groups’ bed- 
disability days differs, 0 will differ from zero. This parameter can be esti- 
mated by replacing A2 by A2* in equation (5). 
15.1.2  Differences in Research Productivity 
(Scientific Opportunity) across Diseases 
The preceding model is based on the assumption that the effect of fund- 
ing on the probability of finding a cure is the same across diseases. This 
assumption is clearly unrealistic,  and it is desirable to relax it.9 We  can 
modify the cure-probability equation to include a disease-specific research 
productivity parameter nz:  P, = T!  X;. The objective function policymak- 
ers seek to maximize is now J* = NIP,  + N2P2  = N1.5r,Xy  + N2n2X;,  and 
the optimal expenditure on research on disease i is now 
(6)  InX, = constant  + [1/(1 - a)]lnN!  + [l/(l - a)]lnn2 
The research-productivity  parameters  i enter the objective function and 
the optimal expenditure equation in the same way as the disease incidence 
measures A’,. Research expenditure should be an increasing function of 
scientific opportunity as well as of disease burden. This implication is con- 
sistent with the views expressed by government officials: “It is vital that the 
allocation of medical research dollars takes into account several factors, 
including scientific opportunity, public health need, gaps in knowledge, as 
well as societal and economic burden of the disease/condition.” ’” 
8. NIH officials acknowledge that “research funding decisions will also reflect concerns 
about equity among groups of potential beneficiaries of the research as defined in terms of 
age, sex, and ethnic origin. Certain criteria favor one group over another. For example, mor- 
tality rates and measures of the impact on functioning may favor the elderly whereas mea- 
sures of economic impact, such as lost productivity, would favor younger citizens” (NIH 
Director Varmus’s responses to questions from Senator Slade Gordon, Labor, HHS, Educa- 
tion Subcommittee Hearing, NIH appropriations for FY  1996, 18 May 1995). 
9. Henderson and Cockburn (1996) have studied the determinants of research productivity 
of pharmaceutical firms, using patents and scientific papers as measures of research output. 
10. Office of Science Policy, NIH Response to Congressional Questions, June 1996. Garber 
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I believe that the CRISP data can eventually be  exploited to obtain 
indicators of (changes in) the relative productivity of research on different 
diseases. The data will enable us to determine, for example, the extent to 
which research related to a given disease tends to be concentrated in rap- 
idly growing and advancing scientific fields (e.g., molecular genetics) as 
opposed to mature fields. They will also allow us to quantify the extent to 
which research on a disease utilizes innovative research techniques (e.g., 
protein engineering), and how much the distribution  of  techniques has 
changed over time. 
At present, however, we  must treat IT,  as unobservable. If research pro- 
ductivity is  uncorrelated across diseases with disease burden,  that is,  if 
differences in supply (or cost of achieving progress) are uncorrelated with 
differences in demand  (or benefits of  achieving progress), estimation of 
equation (5) will  yield an unbiased estimate of  the relationship between 
research expenditure and disease burden. It is possible, however, that N 
and IT  are negatively correlated: the diseases that impose the heaviest bur- 
den do so, in part, because of  the low productivity of  past research on 
those diseases (which should also have resulted in relatively low research 
funding on them). If  this is  the case, then the omission of   IT^  from the 
research expenditure equation would bias the estimated coefficient on In 
N, toward zero. In particular, although the theory implies that the coeffi- 
cient on In N,  should be greater than one, we should not be surprised if we 
obtain estimated coefficients smaller than one; in other words, if we fail to 
observe this kind of “increasing returns.” 
In future research, I hope to directly estimate the contribution of medi- 
cal research expenditure to subsequent progress against disease, by analyz- 
ing the correlation across diseases between research investment and in- 
dicators  of  progress,  such as reductions in potential  life years  lost.”  I 
recognize, however, that heterogeneous, unobserved research productivity 
is likely to lead to overestimates of the average return to research expendi- 
ture. Diseases receiving the greatest research funding are presumably those 
for which research productivity is highest. The slope of  the relationship 
respond to scientific advances, technology trends, and changes in the political and social en- 
vironment.” 
11. The existing evidence on the contribution of medical research expenditure to subse- 
quent progress against disease is rather  limited. The National Institutes of  Health (1993) 
have produced estimates of cost savings from thirty-four “examples” of health care advances 
resulting from NIH support for applied research and clinical trials. Most focus on a single 
innovation such as a new vaccine, a new diagnostic test, or a particular therapy. But these 
case studies are not necessarily a random sample of all NIH-sponsored research, so they 
may not reveal the “aggregate or average” effect of this research on costs. It is possible, for 
example, that the distribution of cost savings is highly skewed to the right-a  few programs 
confer large cost savings, but the majority confer few-and  that the specific examples chosen 
tend to be concentrated in the upper tail of the distribution. Mushkin (1979) attempted to 
determine econometrically the contribution of biomedical research to reductions in mortality 
and morbidity. But most of her analysis was in an aggregate time-series framework and was 
based on fairly crude measures of biomedical research, such as the number of biomedical 
Ph.D.’s lagged ten years. 572  Frank R. Lichtenberg 
across diseases between research funding and progress exceeds the mean 
of the slopes of the disease-specific relationships.  I2 
15.2  Data Sources and Methods 
15.2.1  Data on Government-Funded Research Expenditures, 
by  Disease 
We have calculated distributions of  government-funded biomedical re- 
search expenditure, by disease, from records of research grants contained 
in NIH’s CRISP system. The CRISP database includes records of  all re- 
search ventures supported by the U.S. Public Health Service since 1972. 
In fiscal year 1995, there were records of 63,289 grants, the total value of 
which was $10.1 billion. Most of this research falls within the broad cate- 
gory of extramural projects: grants, contracts, and cooperative agreements 
conducted primarily by  investigators at universities, hospitals, and other 
research institutions. The projects are funded by  NIH and the Substance 
Abuse and Mental Health Services Administration. A very small number 
of these research grants are funded by the Centers for Disease Control, the 
Food and Drug Administration (FDA), the Health Resources and Services 
Administration, and the Agency for Health Care Policy and Research. 
CRISP also contains information on intramural research programs con- 
ducted by  scientists employed by  the FDA and the various institutes of 
the NIH. 
Each record reports the name of the investigator, the name and address 
of his or her organization (e.g., university and department), the title (and 
in many cases an abstract) of the project, the administering organization 
(e.g., National Cancer Institute), the award amount (including both direct 
and indirect costs), the type of award, and a number of (generally about 
fifteen) indexing terms assigned by  Technical Information Specialists in 
the  Research Documentation  Section, lnformation  Systems Branch, of 
NIH’s Division of Research Grants. The indexing process is governed by 
the CRISP thesaurus, which is the “controlled vocabulary used to assign 
indexing terms for the CRISP System, and to retrieve subject-related infor- 
mation from it.” 
The number of distinct indexing terms in the CRISP thesaurus is quite 
large (about nine thousand), but most of these terms are organized into 
12. The reasoning underlying this is the same as that underlying Gary Chamberlain’s (1984) 
argument that estimation of production functions using data for a cross-section of firms will 
result in  overestimates of the returns to factors of  production,  such as labor. Firms with 
exogenously higher productivity (due, e.g., to greater managerial ability) will employ more 
workers. Chamberlin’s  point concerns the coefficient  of one variable only-labor  in a produc- 
tion function framework. If more than one variable is involved, their coefficients will  not 
necessarily be biased toward zero: The direction of bias depends on the entire covariance 
matrix. Not all the coefficients on all the In  Nz  variables will be biased toward zero. The Allocation of Publicly Funded Biomedical Research  573 
a small number of  hierarchical classification schemes, including one for 
diseases. Table 15.3 illustrates the disease classification; it is similar to the 
International Classification of Diseases, the system used for reporting di- 
agnoses in most health-related data. There are thirty-five disease catego- 
ries at the highest level of aggregation. Within each of these is a series of 
more specific disease categories. Space limitations prevent us from display- 
ing the entire “tree structure” of diseases (which includes about twenty- 
nine hundred items), but to illustrate the classification system we show the 
second level classification of “nervous disorders” and a branch leading to 
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a “fifth level” disease (with no further subcategories), lymphocytic chorio- 
meningitis. 
This disease classification scheme enables us to compute distributions 
of research grants and dollars by disease, at various levels of aggregation.” 
How accurate will these distributions be? Recently the Office of the Direc- 
tor of NIH prepared a report that included estimates of NIH fiscal year 
1994 research support by disease. These figures, based on data provided by 
NIH institutes, centers, and divisions (ICDs), “reflect NIH-wide resources 
devoted to research on the listed diseases . . . [and] generally do not corre- 
spond to budget figures for the ICD identifying the cost data.”I4 For six- 
teen randomly selected diseases, I compared fiscal year  1994 funding as 
reported there with the number of fiscal year 1995 grants citing the disease 
contained in the fiscal year 1995 CRISP database. 
The raw data are reported in table 15.4. A scatter plot of the logarithms 
of these two variables is shown in figure 15.2; their correlation coefficient 
is .91. Despite differences in timing and unit of measurement, the two es- 
timates of relative research support by  disease are quite similar, suggest- 
ing that the CRISP data are reasonably reliable up to a first-order approxi- 
mation. 
As NIH officials observe, much NIH-sponsored research is basic in na- 
ture and, although “scientific advances would not have been possible with- 
out  continuing  insight  and  understanding  regarding  the  fundamental 
mechanisms of life and disease . . . basic research linkages to health care 
advances are complicated, long-term, and impossible to allocate clearly” 
(NIH 1993,3). Therefore, many research grants do not refer to any disease 
(even though the research may ultimately lead to breakthroughs  in  the 
treatment of that disease). In other words, the grants fall into two catego- 
ries: those that have been assigned to at least one disease and those that 
have not been assigned.I5  My estimates of research activity by disease are 
based only on grants that have been assigned.16 Due to the logarithmic 
specification of equation (6), the validity of my  parameter estimates does 
not require me to reliably measure the absolute level of research funding, 
by  disease; their validity is predicated  only on reliable measurement of 
13. Data on the disease distribution of priuufe R&D sponsored by  pharmaceutical firms 
are available from the Pharmaceutical Research and Manufacturers Association’s Annual 
Survey of companies. Unfortunately, the private R&D data are disaggregated into only about 
seven broad categories. Figure 15.1 shows the percentage distributions of both private and 
government R&D, by these categories. Public R&D seems to be more concentrated on diges- 
tive/genitourinary and neoplasm/endocrine/metabolic  diseases, and less concentrated on in- 
fective/parasitic, nervous system, and cardiovascular diseases than private R&D. 
14. NIH (1995), table 1. 
15. This distinction resembles the distinction made in industrial R&D between basic and 
16. When two or more diseases are cited by  a grant, I assign the entire amount of funding 
applied research. 
for the grant to each of the diseases cited. ,&&*-  0  0.05  0.1  0.15  0.2  0.25  0.3  0.35  0.4  0.45 
Share 
G* 
Shares of public and private health R&D allocated to major disease  Fig. 15.1 
categories in 1982 
Sources: Public R&D: 1982 CRISP file; Private R&D: PhRMA Annual Survey. 
Table 15.4  Comparison of Fiscal Year  1994 Funding with Fiscal Year  1995 Grants 
Citing the Disease, for Sixteen Randomly Selected Diseases 
FY 1994 Funds 
Disease/Disorder  FY 1995 Grants  (million %) 
Diabetes  1,390  292 
Epilepsy  338  52 
Asthma  345  66 
Arthritis  476  191 
Atherosclerosis  650  116 
Multiple sclerosis  123  78 
Obesity  474  83 
Osteoporosis  288  92 
Parkinson's  253  68 
Psoriasis  53  3 
Sickle cell anemia  278  54 
Suicide  94  17 
Tuberculosis  248  50 
Pneumonia and influenza  230  60 
Schizophrenia  458  111 
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Fig. 15.2  Relationship between estimated NIH research funding, by disease, and 
number of NIH grants citing disease 
rrlutive research funding, or activity. Table 15.5 shows the fraction of 1972 
and 1995 research grants whose indexing terms referred to any (at least 
one) disease and to specific diseases (at the highest level of aggregation) 
in the CRISP classification. In both years, about half of the grants referred 
to  at least  one disease.I7 This is  consistent  with NIH’s statement  that 
“slightly over half, on average, of each Institute’s budget supports the best 
research grant proposals regardless of specific applicability to prevention 
and treatment of a disease, but in expectation that their results will con- 
tribute to advances against diseases within their purview as well  as dis- 
eases in other Institutes and to our knowledge generally.” Relative empha- 
sis on different diseases has been reasonably stable: the correlation across 
diseases (excluding pathology) between the 1972 and 1995 fractions is .85. 
15.2.2  Data on Disease Burden, Prevalence, and Incidence 
As indicated in equation (4) above, rather than treating disease burden 
N (or reduction in the quantity and quality of life) as a scalar, I regard it 
as an index of a number of disease mortality  and morbidity  attributes. 
Data on these attributes are obtained from two sources: the Vital Statis- 
tics-Mortality  Detail file, a virtually  complete census of  deaths in the 
United  States, and the National Health  Interview Survey, a continuing 
nationwide  survey of households for which a probability sample of the 
17. The increase in this fraction, from 49 percent in  1972 to 57 percent in  1995, appears 
to be attributable to the large increase (from 9 to 24 percent) in the fraction of grants refer- 
ring to “pathology.” The Allocation of Publicly Funded Biomedical Research  577 
Table 15.5  Percent of 1972 and 1995 NIH Grants Referring to Any Disease and to 
Specific Diseases 
Disease (Ranked by  Yo  of  Yo  of 
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civilian  noninstitutionalizedI8 population  of  the  United  States is inter- 
viewed  by  the U.S. Bureau of the Census regarding the health and other 
18. It should be pointed out that the restriction of the NHIS to the civilian population not 
confined to institutions affects the estimated prevalence of chronic conditions. Omission of 
the institutionalized population reduces the prevalence estimates, especially for the elderly, 
because the proportion of persons in institutions who have chronic conditions is high. These 
estimates do not indicate the prevalence in the total population. 578  Frank R. Lichtenberg 
characteristics of each member of the household. (The sample for the years 
1990-92  was composed  of  142,638 households containing 368,075 per- 
sons.) 
Our use of  these two data sources reflects my  belief that to obtain a 
reasonably complete accounting for disease burden, one must consider 
data on both the dying and the living. Analysis based on only one source 
will almost surely be subject to considerable sample selection bias. 
Premature Mortality Data 
The measure of disease burden  I computed from the mortality file is 
potential life years lost before age sixty-five, by disease.I9  The latter is de- 
fined as the summation of (65 -  age-at-death) for decedents under sixty- 
five. This is a standard measure of disease burden, or (lack of) progress 
against disease, in health statistics. It has the drawback of giving no weight 
at all to deaths of people aged sixty-five and over. 
Data on Prevalence of Selected Chronic Conditions 
Collins (1997) presents statistics on the prevalence of selected chronic 
conditions in the United States during 1990-92  by age, sex, race, family 
income, and geographic region, derived from data collected in the Na- 
tional Health Interview Survey (NHIS). He also reports the percent  of 
selected conditions that cause activity limitation, the percent for which a 
physician was consulted, and the percent that caused hospitalization. 
All information collected during the survey is from responsible family 
members residing in the household. Methodological  studies have shown 
that chronic conditions are generally underreported in interview surveys. 
Respondents in health interviews tend to report conditions of which they 
are aware and about which they are willing to report to the interviewer. 
Reporting is better for conditions that have made a significant impact on 
affected individuals and their families. Conditions that are severe or costly, 
or are being treated, tend  to be better reported than conditions having 
less impact. Methodological studies have also indicated that inclusion of 
a checklist of descriptive condition titles as part of the interview question- 
naire increases the probability that a respondent will recognize the terms 
and report those of which the respondent is aware. 
The current procedure for collecting information on chronic conditions 
was established in 1978. Currently, six categorical lists of selected chronic 
conditions are included in the NHIS questionnaire: circulatory conditions; 
respiratory conditions; digestive conditions; impairments and conditions 
of the nervous system and sense organs; conditions of the skin and subcu- 
19. Demographic information on the death certificate is provided by the funeral director 
based on information supplied by an informant, Medical certification of cause of death is 
provided by a physician, medical examiner, or coroner. The Allocation of Publicly Funded Biomedical Research  579 
taneous tissue and of  the musculoskeletal system and connective tissue; 
and endocrine, nutritional,  and metabolic diseases and immunity disor- 
ders, diseases of the blood and blood-forming organs, and conditions of 
the genitourinary system. Each family in the NHIS is questioned on only 
one of these six lists, selected on a predetermined basis. Therefore, each 
list is administered to only one-sixth of the total NHIS sample each year. 
For some items, responses are based on the following question: “During 
the past 12 months did anyone in the family (read names) have . . .  ?”  For 
others, responses are based on the question “Does anyone in the family 
(read names) now  have . . . ?”  For the rest, responses are based on the 
question “Has anyone in the family (read names) ever had . . . ?” Estimates 
for days of disability caused by chronic conditions are based on the num- 
ber of disability-days reported for the two weeks before interview. 
The survey includes data only on persons living in the household at the 
time of interview. Thus the experience of persons who died prior to the 
time of interview is excluded from the data. Also excluded is the experi- 
ence of persons who were institutionalized or who were members of  the 
armed forces at the time of the household interview. 
In these data, “prevalence” is defined as the average number of some 
item existing during a specified interval of  time-usually  referred to as 
“period prevalence”-rather  than the number of  some item existing at a 
given point in time-usually  referred to as “point prevalence.” Chronic 
conditions are defined as conditions that either were  first noticed three 
months  or more before the date of  interviews, or belong to a group of 
conditions considered chronic regardless of when they began. 
The data presented represent the prevalence of conditions, not the prev- 
alence of persons with a chronic condition. However, for most conditions, 
the condition prevalence and the person prevalence are almost identical.20 
15.3  Preliminary Estimates 
15.3.1  Premature Mortality 
The first measure of disease burden I analyze is potential life years lost 
before age sixty-five (PLYL). Data on PLYL in 1980 and government re- 
20. There are some instances in which large variations  are present; these occur for two 
different reasons. The first is that a prevalence estimate of a condition may include more 
than one of the specified checklist items or a checklist item and a specified “other condition” 
item that falls into the same International Classification of Diseases category as the checklist 
item. The second reason is that some prevalence categories shown are a combination of other 
categories and, as a result, a person may have more than one of the conditions that are added 
to form the combined category. The concept of condition prevalence is generally used in 
NHIS because specific health indexes such as limitation of activity and disability days can 
be  ascribed  to specific conditions. In addition, prosthetic and pharmaceutical  treatment 
modes are more condition specific than person specific. 580  Frank R. Lichtenberg 
Table 15.6  Life Years Lost before Age Sixty-Five in 1980, and Public R&D Expenditure in 
1982, Fourteen Major Disease Categories 
Life Years Lost  Public R&D 
before Age Sixty-Five  Expenditure in 1982 
Disease/Disordera  in 1980  (million $) 
Diseases of the circulatory system (390-459) 
Neopiasms (140-239) 
Congenital anomalies (740-759) 
Diseases of the digestive system (520-579) 
Diseases of the respiratory system (460-519) 
Diseases of the nervous system and sense 
organs (320-389) 
Endocrine, nutritional, and metabolic diseases 
and immunity disorders 
Infectious and parasitic diseases (001-1 39) 
Mental disorders (290-319) 
Diseases of the genitourinary system (580-629) 
Diseases of the blood and blood-forming 
Diseases of the musculoskeletal system and 
Complicaitons of pregnancy, childbirth, and the 

































."umbers  in parentheses are International Classification of Diseases codes. 
search funding, in 1982, for fourteen major disease categories are shown, 
in descending PLYL order, in table 15.6. Diseases of the circulatory system 
and neoplasms are, by  far, the diseases with the largest tolls in terms of 
premature death. While the  research funding for these two  diseases is 
among the highest for all diseases, R&D funding for two other diseases 
with much smaller burdens exceeds the funding for the first two diseases, 
in one case by  a large amount. Nevertheless, as the scatter plot in figure 
15.3 and the following regression indicate, there is a very strong positive 
relationship across the entire sample between life  years lost  and public 
R&D expenditure (t-statistics in parentheses): 
ln(RD82)  = -0.464  + 0.3551n(LYL80) + e  R2 = ,459 
(0.34)  (3.19)  N  = 14. 
Life years lost in 1980 explains almost half of the variation across diseases 
in 1982 research expenditure. However, contrary to the implication of my 
simple  theoretical  model  of  research  allocation,  the  coefficient  on 
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Fig. 15.3  Relationship between government research funding, by  disease, in  1982, 
and life years lost before age sixty-five, by disease, in 1980 
to a negative correlation between the regressor and the omitted research- 
productivity variable.*' 
Life years lost can be classified by  sex, race, educational attainment, 
and other characteristics, so we can investigate whether premature mortal- 
ity among certain demographic groups tends to be associated with espe- 
cially high government research funding. Sixty percent of life years lost 
before age sixty-five are lost by males, and 25 percent are lost by nonwhites 
(who make up about  10 percent of  the population), reflecting the lower 
life expectancy of these two groups. The proportion of life years lost by 
men and by nonwhites varies considerably across diseases. Whites account 
for 81 percent of life years lost to neoplasms but for only 53  percent of 
those due to  diseases of the blood and blood-forming organs. Men account 
for 81 percent  of  life years lost to infectious and parasitic diseases but 
21. I  obtain quite similar results when I use data covering other time periods or when I 
substitute life years lost before age eighty for life years lost before age sixty-five. (About twice 
as many life years are lost before age eighty as are lost before age sixty-five; the correlation 
across  diseases  between  the two  is  very high-.98.)  The correlation coefficient between 
ln(RD82) and In(LYL80) is ,677. The correlation coefficients between the log of the number 
of year t(t = 1980, 1995) NIH grants referring to disease i and the log of life years lost before 
age j(j  = 65, 80) to disease i in year t are as follows: 
t = 1980  t = 1995 
j  = age 80  ,764  ,710 
j  = age 65  .739  ,677 582  Frank R. Lichtenberg 
for only 28 percent of life years lost to musculoskeletal and connective- 
tissue diseases. 
The  matrix  of  correlation  coefficients for four  variables--ln(RD82), 
ln(LYL80), and the fractions of life years lost to men (%MALE) and to 
whites (%WHITE)-are  reported in table 15.7. Public R&D investment is 
significantly positively correlated with the fractions of life years lost to 
men and (especially) to whites, as well  as with the total number of life 
years lost. Indeed, %WHITE is more strongly correlated with R&D than 
total life years lost is. (A scatter plot  of ln[RD82] against %WHITE is 
shown in fig. 15.4.) But as the second column of coefficients reveals, both 
%MALE and YOWHITE  are significantly positively correlated with total 
life years lost: the diseases associated with the greatest number of prema- 
ture deaths are those for which men and whites account for the greatest 
Table 15.7  Correlation Matrix for Four Variables 
In( RD82)  ln(LYL80)  %MALE 
ln(LYL80)  0.67714 
(0.0078) 
%MALE  0.55375  0.56093 
(0.0399)  (0.0369) 
%WHITE  0.75643  0.88477  0.50235 
(0.00  1  7)  (0.0001)  (0.0672) 
Note: Numbers in parentheses are p-values. 
I  I 
I  I 
2 
50.0%  55.0%  60.0%  65.0%  70.0%  75.0%  80.0% 
Life-Years Lost lo  White Persons as % of Total Life-Yean Lost in 1980 
Fig. 15.4  Relationship across diseases between public R&D expenditure and 
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fractions  of  life  years  lost.  We  therefore  need  to  determine  whether 
%MALE and %WHITE have significant effects on public R&D, control- 
ling for total life years lost (although our ability to determine this will be 
hampered by multicollinearity). The appropriate regressions are 
ln(RD82)  =  -0.164  + 0.2801n(LYL80) + 1.1  1 %MALE + e 
ln(RD82)  =  -0.813 + 0.0191n(LYL80) + 6.56 %WHITE + e  R2  =.573 
R2  =SO3 
(0.12)  (2.08)  (0.99)  N = 14, 
(0.64)  (0.09)  (1.71)  N=14. 
The coefficient on %MALE is insignificant and the inclusion of this vari- 
able only slightly reduces the coefficient on ln(LYL80). In contrast, the 
coefficient on %WHITE is marginally significant, even in the presence of 
the other regressor, which becomes insignificant (with a t-statistic of only 
0.09) when %WHITE is included. We also estimated an alternative func- 
tional form of the relationship RD82 =  flLYL80, %WHITE): 
ln(RD82)  = 2.29 + 1.351n(LYL80 x  %WHITE) 
(1.14)  (1.90) 
-1.301n[LYL80  x  (1 - %WHITE)] + e  R2  =.560, 
(1.44)  N  = 14. 
These estimates indicate that research expenditure is positively correlated 
with life years lost by whites but not by nonwhites; the coefficient on the 
latter is negative, but itsp-value is only .18. The two coefficients are virtu- 
ally equal in magnitude and opposite in sign; if one imposes that restric- 
tion (which is not rejected by the data), the estimates are 
ln(RD82) = 2.72 + 1.47ln[%WHITE/(l -  %WHITE)] + e  RZ  = .558 
(8.40)  (3.89)  N  = 14. 
The data are highly consistent with the hypothesis that the amount of 
publicly funded research on a disease decreases with the share of life years 
before age sixty-five lost to the disease that are lost by nonwhites. A pos- 
sible explanation for this finding is that lack of  scientific knowledge is a 
less important cause of premature mortality among nonwhites than it is 
among whites. Nonwhite premature mortality may be due, to a greater 
extent, to poor diet, reduced utilization of medical care, or other factors. 
In other words, it is plausible that the health status of nonwhites tends to 
be well below the frontier of medical knowledge, whereas the health status 
of whites tends to be on, or closer to, the frontier. The purpose of biomedi- 
cal research is to shift the frontier outward, and the allocation or “direc- 
tion” of research should depend (more) on the distribution of the disease 
burden of those on, or close to, the frontier. If cures for diseases that im- 584  Frank R. Lichtenberg 
pose a heavy toll on minorities have already been found, then the produc- 
tivity of further research on those diseases may be quite low. 
The relative lack of research  on diseases borne disproportionately  by 
minorities may also be due to other reasons and may not be efficient. It 
may reflect the relatively low representation of minorities among the ranks 
of biomedical scientists. The National Science Foundation monitors the 
participation of women and minorities in science and engineering and has 
adopted some policies to increase their participation. 
15.3.2  Prevalence and Severity of Chronic Conditions 
in the (Living) Population 
Table 15.8 presents data on the number of FY1995 research grants men- 
tioning chronic conditions surveyed in the National Health Interview Sur- 
vey  and the number of people having, and limited in activity by,  these 
conditions.22  The condition mentioned in the most (1,807) research grants 
is diabetes. About seven million Americans suffer from diabetes, according 
to this household survey; about one-third of them are limited in activity 
by this condition. Although arthritis is far more prevalent, afflicting thirty- 
two million Americans, the number of research grants mentioning it (609) 
is much smaller. 
Table 15.9 presents correlation coefficients of the logarithms of  these 
variables and related measures of condition severity. This table indicates 
that the number of research grants mentioning a chronic condition has a 
very small and insignificant correlation with the number of people with 
the condition and with the number who have seen a physician about that 
condition. Research activity is weakly positively related (p-value = .08) to 
the number of  people who have been hospitalized for a condition. It is 
very strongly positively related (p-value = ,0003) to the number of people 
whose activities are limited by that condition. Somewhat surprisingly, re- 
search activity is significantly positively correlated with the proportion of 
people who have seen a doctor or been hospitalized, as well as those whose 
activities are limited.23 
The determinants of the number of research grants citing chronic condi- 
tions are further analyzed in table  15.10. The first column presents the 
regression  of  ln(NGRANTS95) on  a  measure of  condition prevalence 
22. In this section the measure of public research activity I use is the number of  grants 
rather than the dollar value of those grants. For technical reasons, the former is much easier 
to compute. Substitution of the former for the latter will not affect my results if the average 
size of grants is uncorrelated  across conditions with the number of grants. In the future I 
plan to compute the distribution of dollars by condition and to integrate the premature mor- 
tality and chronic-condition prevalence analyses. 
23. This is particularly surprising since, as the second column of table 15.9 indicates, these 
proportions are significantly inversely related to prevalence per se: conditions that are more 
prevalent tend to be less severe (is., associated with lower probabilities of  hospitalization, 
activity limitation, and physician consultation). Table 15.8  Number of FY1995 Research Grants Citing, and Number of People 
Reporting and Limited in Activity by, Major Chronic Conditions 




















































































































High blood pressure (hypertension) 
Diseases of retina 
Arthritis 





Blindness and other visual impairments 
Liver diseases including cirrhosis 
Cerebrovascular disease 
Deafness and other hearing impairments 
Ischemic heart disease 
Multiple sclerosis 
Speech impairments 
Malignant neoplasm of breast 
Cataracts 
Glaucoma 
Enteritis and colitis 
Congenital heart disease 
Disease of the esophagus 
Malignant neoplasms of stomach intestines 





Tachycardia or rapid heart 
Heart rhythm disorders 
Malignant neoplasm of prostate 
Ulcer gastric duodenal andlor peptic 
Malignant neoplasms of the skin 
Hardening of arteries 
Gastric ulcer 
Benign neoplasm of breast 
Cleft palate 
Gastritis and duodenitis 
Nofes: NGRANT = Number of FY  I995 grants mentioning condition. N  = Average num- 
ber of people  (in thousands) in  1990-92  reporting that they have the condition. NLA = 
Average number of people (in thousands) in 1990-92  reporting that their activities are limited 
by  the condition. Only conditions cited by fifty or more grants are listed. Table 15.9  Correlations between Research Activity and PrevalencelSeverity of 
Chronic Conditions 
LGRANTS  LN  LNLA  LNHOSP 
LGRANTS: log(no. of research grants) 
LN: log(no. of people w.  condition) 
LNLA: log(no. w.  limited activity) 
LNHOSP: log(  no. hospitalized) 
LNPHYS: log(no. seeing physician) 
LA: '70 w.  limited activity 
HOSP: '70  hospitalized 
PHYS: YO  seeing physician 




















































Note:  Figures in parentheses are probability values. 
Table 15.10  Determinants of Number of FY 1995 Research Grants Mentioning 
Chronic Conditions (N = 54) 
Equation  1  Equation 2  Equation 3 
MN) 
YOLA 
In(N X %LA) 
In"  X  (1 -  %LA)] 
%INCOME < $10,000 
%AGE < 18 











2.09  3.82 
(1.31)  (2.81) 














Notes;  The dependent  variable is the log of  the number of  FYI995 grants. N = Average 
number of people (in thousands) in  1990-92  reporting that they have the condition. %LA 
= Fraction of people reporting that their activities are limited by the condition. '%INCOME 
<  $10,000 = Fraction of people with household income <  $10,000. %AGE < 18 = Fraction 
of people under eighteen years of age. YOAGE  > 75 = Fraction of  people over seventy-five 
years of age. Numbers in parentheses are t-statistics. The Allocation of Publicly Funded Biomedical Research  587 
(In“])  and severity (%LA). As one might expect given the simple correla- 
tions in the previous table, only the severity measure has a significant posi- 
tive effect on research activity. In the second column, I estimate an alterna- 
tive functional form of the relationship; the regressors are the logarithms 
of  the number of  people with  the condition whose activities are (N X 
%LA) and are not (N  X [l -  %LA]) limited by the condition. The coeffi- 
cient on the former is positive and highly significant, indicating that the 
amount of public research about a chronic condition increases with the 
number of people whose activities are limited by  that condition.24  More- 
over, the amount of public research is significantly inversely related to the 
number of people who have a condition but whose activities are not limited 
by it. This could conceivably signify that, the greater the number of people 
who have a condition but are not seriously affected by  it, the greater the 
odds that an adequate treatment for the condition already exists, and the 
less worthy that condition is of further research. This inverse relation be- 
comes insignificant, however, when we  include (in column 3) measures of 
the income and age distribution of  persons reporting the condition. This 
regression indicates that there tends to be more research about chronic 
conditions that are prevalent among people living in low-income (below 
$10,000) households, and that are prevalent among the young (under age 
eighteen) and the old (above age seventy-five). This suggests that the poor, 
the young, and the very  old may derive disproportionately large benefits 
from government-sponsored biomedical research. In the previous section 
I reported that the amount of publicly funded research on a disease de- 
creases with the share of life years before age sixty-five lost to the disease 
that are lost by nonwhites. Since nonwhites are more likely to be poor than 
whites, it is surprising that chronic conditions prevalent among the poor 
tend to be more intensively researched. 
15.4  Summary 
I have developed a simple theoretical model of  the allocation of  the 
applied component of  public biomedical research expenditure-the  ap- 
proximately 50 percent that is of direct, near-term relevance to specific 
diseases-and  presented some empirical evidence about the determinants 
of this allocation. The implications of the theoretical model are consistent 
with government officials’ descriptions of the allocation process: the struc- 
ture of expenditure should depend upon research productivity (or “scien- 
tific opportunity”) as well as on public health need, or the societal and 
economic burden of the diseaselcondition. 
Although we  lack, at this point, useful indicators of research productiv- 
24. As in the analysis of premature mortality, however, the elasticity is significantly less 
than unity. 588  Frank R. Lichtenberg 
ity (i.e., of the cost of achieving research advances), we have a number of 
measures of disease burden (i.e., of the potential beneJit of achieving these 
advances). Analysts of technological change typically have data on neither 
the costs nor the benefits of technical advance. Failure to measure research 
productivity will not necessarily bias my estimates; if it does, it seems likely 
to bias them toward zero. 
I calculated distributions of government-funded biomedical research ex- 
penditure, by  disease, from records of all research projects supported by 
the U.S.  Public Health Service; in fiscal year 1995, there were records of 
63,289 projects whose total value was $10.1 billion. Some research expen- 
diture cannot be assigned to specific diseases, in some cases because the 
research being conducted is basic in nature. The distribution of research 
expenditure by disease that I constructed is quite similar to one calculated 
by NIH based on data provided by NIH institutes, centers, and divisions 
(ICDs) designed to “reflect NIH-wide resources devoted to research on 
the listed diseases” (as opposed to budget figures for the ICD identifying 
the cost data). 
I performed an empirical examination of the relationship of public re- 
search expenditure to a number of measures of disease burden. To  avoid 
“sample selection bias,” and to obtain a reasonably complete accounting 
of  disease  burden,  I  utilized  data on  both  the  dying  (from  the  Vital 
Statistics-Mortality  Detail file) and the living (from the National Health 
Interview Survey). 
The mortality-related measure of disease burden I use is life years lost 
before age sixty-five. I found a very strong positive relationship across dis- 
eases between total life years lost and public R&D expenditure (although 
the slope of this relationship was smaller than that implied by the theory, 
perhaps due to failure to measure research productivity). Further analysis 
indicated that research expenditure is positively correlated with life years 
lost by whites but not with life years lost by nonwhites. In other words, the 
amount of publicly funded research on a disease decreases with the share 
of life years before age sixty-five lost to the disease that are lost by non- 
whites. A possible explanation  for this finding is that lack  of scientific 
knowledge is a less important cause of premature mortality among non- 
whites than it is among whites. 
Disease prevalence and severity data for the (living) population provide 
additional indicators of disease burden. I found that the number of  re- 
search grants mentioning a chronic condition has a very low and insignifi- 
cant correlation with the number of people with the condition and with 
the number  who have  seen a physician about  that condition. Research 
activity is weakly positively related to the number of people who have been 
hospitalized  for a condition, and very strongly positively related to the 
number of people whose activities are limited by that condition. Moreover, 
there tends to be more research about chronic conditions that are prevalent The Allocation of  Publicly Funded Biomedical Research  589 
among people living in low-income households,  and  that are prevalent 
among the young (under age eighteen) and the old (above age seventy-five). 
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